A Phase 1 interventional study of V116 and PNEUMOVAX™23 in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 10th largest by enrollment, is the only one that started in 2021, is the only one in phase 1, and was the 1st registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 20 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2021.
This study's enrollment of 102 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 41st largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 1, and was the 34th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety, tolerability, and immunogenicity of a polyvalent pneumococcal conjugate vaccine (V116) with that of PNEUMOVAX™23 in healthy Japanese adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single 1.0 mL intramuscular (IM) injection of V116 on Day 1.
Biological: V116
Participants receive a single 0.5 mL IM injection of PNEUMOVAX™23 on Day 1.
Biological: PNEUMOVAX™23
Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Also known as: Polyvalent pneumococcal conjugate vaccine (pPCV), Pneumococcal 21-valent Conjugate Vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Also known as: PPSV23
Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included tenderness/pain, redness/erythema, and swelling. The percentage of participants with one or more solicited injection-site AE was reported for each arm.
Time frame: Up to 5 days postvaccination
Percentage of Participants With a Solicited Systemic AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was reported for each arm.
Time frame: Up to 5 days postvaccination
Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)
An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were reported.
Time frame: Up to 62 days postvaccination
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and PNEUMOVAX™23
The serotype-specific OPA GMTs for serotypes common to V116 and PNEUMOVAX™23 were determined using the multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group measures of dispersion (MOD) were not calculated.
Time frame: Day 30 postvaccination
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and PNEUMOVAX™23
The GMCs for serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.
Time frame: Day 30 postvaccination
Serotype-specific OPA GMTs for the Unique Serotypes in V116
The serotype-specific OPA GMTs for serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.
Time frame: Day 30 postvaccination
Serotype-specific IgG GMCs for the Unique Serotypes in V116
The GMCs for serotype-specific pneumococcal IgG antibodies unique to V116 were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.
Time frame: Day 30 postvaccination
Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA
GMTs for the serotypes in V116 and PNEUMOVAX™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.
Time frame: Baseline (Day 1) and Day 30 postvaccination
GMFR From Baseline in Serotype-specific IgG GMCs
GMCs for the serotypes in V116 and PNEUMOVAX™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.
Time frame: Baseline (Day 1) and Day 30 postvaccination
| Milestone | V116 | PNEUMOVAX™23 |
|---|---|---|
| Started | 51 | 51 |
| Completed | 51 | 51 |
| Not completed | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included tenderness/pain, redness/erythema, and swelling. The percentage of participants with one or more solicited injection-site AE was reported for each arm.
| Percentage of Participants | V116 | PNEUMOVAX™23 |
|---|---|---|
| Injection site erythema | 9.8 | 9.8 |
| Injection site pain | 54.9 | 66.7 |
| Injection site swelling | 13.7 | 13.7 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was reported for each arm.
| Percentage of participants | V116 | PNEUMOVAX™23 |
|---|---|---|
| Fatigue | 13.7 | 9.8 |
| Arthralgia | 3.9 | 3.9 |
| Myalgia | 17.6 | 19.6 |
| Headache | 9.8 | 9.8 |
An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were reported.
| Percentage of participants | V116 | PNEUMOVAX™23 |
|---|---|---|
| Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) | 0.0 | 0.0 |
The serotype-specific OPA GMTs for serotypes common to V116 and PNEUMOVAX™23 were determined using the multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group measures of dispersion (MOD) were not calculated.
| Titers | V116 | PNEUMOVAX™23 |
|---|---|---|
| Serotype 3 | 161.08 (NA to NA) | 100.76 (NA to NA) |
| Serotype 7F | 5327.67 (NA to NA) | 4406.11 (NA to NA) |
| Serotype 19A | 1479.82 (NA to NA) | 738.52 (NA to NA) |
| Serotype 22F | 5768.79 (NA to NA) | 3000.50 (NA to NA) |
| Serotype 33F | 33187.25 (NA to NA) | 28831.77 (NA to NA) |
| Serotype 8 | 1287.66 (NA to NA) | 721.85 (NA to NA) |
| Serotype 9N | 6555.82 (NA to NA) | 3466.72 (NA to NA) |
| Serotype 10A | 3608.34 (NA to NA) | 1330.75 (NA to NA) |
| Serotype 11A | 1467.66 (NA to NA) | 603.00 (NA to NA) |
| Serotype 12F | 1356.20 (NA to NA) | 563.99 (NA to NA) |
| Serotype 17F | 8470.21 (NA to NA) | 3293.31 (NA to NA) |
| Serotype 20A | 3542.90 (NA to NA) | 1553.99 (NA to NA) |
The GMCs for serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.
| μg/mL | V116 | PNEUMOVAX™23 |
|---|---|---|
| Serotype 3 | 1.13 (NA to NA) | 0.73 (NA to NA) |
| Serotype 7F | 10.29 (NA to NA) | 4.66 (NA to NA) |
| Serotype 19A | 10.75 (NA to NA) | 4.97 (NA to NA) |
| Serotype 22F | 3.94 (NA to NA) | 1.69 (NA to NA) |
| Serotype 33F | 22.00 (NA to NA) | 14.48 (NA to NA) |
| Serotype 8 | 19.38 (NA to NA) | 10.33 (NA to NA) |
| Serotype 9N | 14.17 (NA to NA) | 5.99 (NA to NA) |
| Serotype 10A | 11.13 (NA to NA) | 5.16 (NA to NA) |
| Serotype 11A | 9.07 (NA to NA) | 4.71 (NA to NA) |
| Serotype 12F | 2.87 (NA to NA) | 0.82 (NA to NA) |
| Serotype 17F | 19.46 (NA to NA) | 6.77 (NA to NA) |
| Serotype 20A | 23.53 (NA to NA) | 11.46 (NA to NA) |
The serotype-specific OPA GMTs for serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.
| Titers | V116 | PNEUMOVAX™23 |
|---|---|---|
| Serotype 6A | 1663.20 (NA to NA) | 464.65 (NA to NA) |
| Serotype 15A | 5030.66 (NA to NA) | 807.16 (NA to NA) |
| Serotype 15C | 3641.84 (NA to NA) | 1565.56 (NA to NA) |
| Serotype 16F | 2459.26 (NA to NA) | 244.49 (NA to NA) |
| Serotype 23A | 2620.19 (NA to NA) | 62.26 (NA to NA) |
| Serotype 23B | 2065.39 (NA to NA) | 167.03 (NA to NA) |
| Serotype 24F | 2742.93 (NA to NA) | 110.53 (NA to NA) |
| Serotype 31 | 1699.54 (NA to NA) | 66.24 (NA to NA) |
| Serotype 35B | 4992.58 (NA to NA) | 349.07 (NA to NA) |
The GMCs for serotype-specific pneumococcal IgG antibodies unique to V116 were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group MOD were not calculated.
| μg/mL | V116 | PNEUMOVAX™23 |
|---|---|---|
| Serotype 6A | 6.38 (NA to NA) | 2.13 (NA to NA) |
| Serotype 15A | 16.39 (NA to NA) | 2.04 (NA to NA) |
| Serotype 15C | 21.42 (NA to NA) | 6.81 (NA to NA) |
| Serotype 16F | 5.57 (NA to NA) | 0.43 (NA to NA) |
| Serotype 23A | 4.14 (NA to NA) | 0.48 (NA to NA) |
| Serotype 23B | 8.56 (NA to NA) | 2.06 (NA to NA) |
| Serotype 24F | 13.99 (NA to NA) | 0.49 (NA to NA) |
| Serotype 31 | 5.25 (NA to NA) | 0.51 (NA to NA) |
| Serotype 35B | 24.61 (NA to NA) | 1.54 (NA to NA) |
GMTs for the serotypes in V116 and PNEUMOVAX™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.
| Ratio | V116 | PNEUMOVAX™23 |
|---|---|---|
| Serotype 3 | 9.86 (7.07 to 13.75) | 6.35 (4.43 to 9.10) |
| Serotype 7F | 19.79 (10.60 to 36.94) | 21.53 (11.79 to 39.30) |
| Serotype 19A | 10.80 (7.27 to 16.04) | 6.74 (4.45 to 10.18) |
| Serotype 22F | 15.14 (8.25 to 27.79) | 18.13 (9.17 to 35.85) |
| Serotype 33F | 11.47 (8.20 to 16.04) | 11.62 (7.91 to 17.06) |
| Serotype 8 | 102.33 (75.07 to 139.50) | 48.14 (32.69 to 70.88) |
| Serotype 9N | 55.49 (31.26 to 98.50) | 40.11 (22.97 to 70.03) |
| Serotype 10A | 31.29 (15.34 to 63.81) | 21.93 (12.29 to 39.11) |
| Serotype 11A | 42.06 (25.15 to 70.32) | 20.68 (12.11 to 35.33) |
| Serotype 12F | 94.74 (54.15 to 165.76) | 44.70 (24.59 to 81.24) |
| Serotype 17F | 23.63 (13.40 to 41.68) | 11.40 (7.07 to 18.40) |
| Serotype 20A | 11.69 (7.27 to 18.81) | 5.94 (4.12 to 8.57) |
| Serotype 6A | 22.76 (12.66 to 40.93) | 8.31 (5.24 to 13.17) |
| Serotype 15A | 10.70 (6.31 to 18.13) | 3.02 (1.67 to 5.43) |
| Serotype 15C | 36.53 (18.49 to 72.15) | 16.72 (9.39 to 29.76) |
| Serotype 16F | 14.74 (8.27 to 26.28) | 1.84 (1.10 to 3.06) |
| Serotype 23A | 46.69 (25.58 to 85.22) | 1.93 (1.05 to 3.56) |
| Serotype 23B | 43.21 (25.15 to 74.23) | 4.43 (3.00 to 6.54) |
| Serotype 24F | 9.21 (5.06 to 16.78) | 0.75 (0.40 to 1.40) |
| Serotype 31 | 27.99 (16.04 to 48.85) | 1.22 (0.75 to 2.01) |
| Serotype 35B | 7.39 (4.32 to 12.67) | 0.56 (0.41 to 0.78) |
| Serotype 6C | 5.63 (3.17 to 9.99) | 4.00 (2.21 to 7.24) |
| Serotype 15B | 35.68 (18.43 to 69.08) | 23.54 (13.35 to 41.50) |
| Serotype 20B | 6.08 (3.16 to 11.71) | 8.89 (5.29 to 14.95) |
GMCs for the serotypes in V116 and PNEUMOVAX™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.
| Ratio | V116 | PNEUMOVAX™23 |
|---|---|---|
| Serotype 3 | 5.92 (4.25 to 8.24) | 4.47 (3.48 to 5.74) |
| Serotype 7F | 23.86 (16.20 to 35.14) | 10.51 (7.57 to 14.58) |
| Serotype 19A | 7.58 (5.51 to 10.44) | 3.52 (2.71 to 4.56) |
| Serotype 22F | 14.68 (9.24 to 23.30) | 6.57 (4.65 to 9.28) |
| Serotype 33F | 21.61 (14.49 to 32.23) | 11.52 (8.24 to 16.13) |
| Serotype 8 | 31.58 (22.46 to 44.39) | 16.71 (12.61 to 22.14) |
| Serotype 9N | 24.26 (16.60 to 35.46) | 10.56 (8.01 to 13.92) |
| Serotype 10A | 15.70 (10.45 to 23.59) | 7.19 (5.13 to 10.07) |
| Serotype 11A | 9.31 (6.51 to 13.31) | 4.64 (3.47 to 6.22) |
| Serotype 12F | 23.87 (15.22 to 37.44) | 6.53 (4.52 to 9.44) |
| Serotype 17F | 20.71 (15.14 to 28.33) | 7.37 (5.60 to 9.69) |
| Serotype 20A | 11.68 (8.14 to 16.77) | 6.19 (4.57 to 8.38) |
| Serotype 6A | 14.01 (8.99 to 21.86) | 4.67 (3.28 to 6.63) |
| Serotype 15A | 32.11 (18.79 to 54.89) | 3.34 (2.52 to 4.44) |
| Serotype 15C | 42.20 (25.71 to 69.25) | 11.50 (7.83 to 16.88) |
| Serotype 16F | 21.00 (14.13 to 31.23) | 1.52 (1.33 to 1.73) |
| Serotype 23A | 18.42 (12.28 to 27.63) | 2.26 (1.67 to 3.06) |
| Serotype 23B | 14.04 (9.14 to 21.58) | 3.22 (2.55 to 4.06) |
| Serotype 24F | 31.58 (18.26 to 54.60) | 1.15 (1.01 to 1.31) |
| Serotype 31 | 17.97 (12.37 to 26.10) | 1.64 (1.28 to 2.09) |
| Serotype 35B | 16.93 (11.99 to 23.90) | 1.10 (1.05 to 1.15) |
| Serotype 6C | 5.94 (4.25 to 8.30) | 2.21 (1.79 to 2.74) |
| Serotype 15B | 11.14 (7.39 to 16.78) | 8.61 (6.14 to 12.08) |
Collected over Up to 62 days postvaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V116 | 0/51 (0%) | 0/51 (0%) | 30/51 (58.8%) |
| PNEUMOVAX™23 | 0/51 (0%) | 0/51 (0%) | 35/51 (68.6%) |
| Event | V116 | PNEUMOVAX™23 |
|---|---|---|
| Injection site painGeneral disorders | 28/51 | 34/51 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/51 | 10/51 |
| FatigueGeneral disorders | 7/51 | 5/51 |
| Injection site swellingGeneral disorders | 7/51 | 7/51 |
| Injection site erythemaGeneral disorders | 5/51 | 5/51 |
| HeadacheNervous system disorders | 5/51 | 5/51 |
| PyrexiaGeneral disorders | 0/51 | 3/51 |
| Age, Continuous(Years) | V116 | PNEUMOVAX™23 | Total |
|---|---|---|---|
| Mean | 63.1 ± 13.7 | 64.0 ± 12.7 | 63.6 ± 13.2 |
| Sex: Female, Male(Participants) | V116 | PNEUMOVAX™23 | Total |
|---|---|---|---|
| Female | 28 | 24 | 52 |
| Male | 23 | 27 | 50 |
| Ethnicity (NIH/OMB)(Participants) | V116 | PNEUMOVAX™23 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 51 | 51 | 102 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | V116 | PNEUMOVAX™23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 51 | 51 | 102 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2021 to primary completion in Apr 2021, 2 months.
Results were first posted in Jul 2023, 2 years 3 months after primary completion.
Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine